anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A randomized placebo-controlled clinical trial will be conducted to evaluate the impact of Cinnamonforce™ on different serum markers related to diabetes and lipid management. Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule. Based on inclusion and exclusion criteria outlined in 13A, seventy (70) participants will be randomized using a computer-derived random number generator to the treatment group where they will receive Cinnamonforce™ or to the control group where they will receive a placebo. The manufacturer of Cinnamonforce™, New Chapter, will generate the treatment allocations and retain these in sealed opaque envelopes until the end of the trial. Patients, investigators, and statisticians will be blinded until the end of the trial. Participants will be administered 140 mg of Cinnamonforce™ twice daily or placebo of identical size, shape, colour and odour. Patients will be instructed to take two capsules (140 mg) at the end of each of the two largest meals of the day for 3 months. Compliance will be assessed by pill count.Participants will be asked to come in for assessment at predefined time points including: baseline, 2 weeks, 4 weeks, 8 weeks and end point (13 weeks). At each time point, objective and subjective measurements will be obtained.

The primary objective measures will consist of fasting blood glucose, insulin and HA1C. Secondary biochemical measures will include a lipid panel (total cholesterol,triglycerides, HDL and LDL). Other secondary objective measures will consist of blood pressure, weight, body mass index (BMI), waist/hip measurements, patient self-monitoring of blood glucose and homeostasis model assessment of insulin resistance (HOMA-IR) calculations. Liver and kidney toxicity of the intervention will be assessed through serum measurements of a liver panel (AST, ALT, total protein, albumin, alkaline phosphatase, total bilirubin and direct bilirubin), creatinine and blood-urea-nitrogen (BUN). Coagulability effects will be measured (PT, PTT, fibrinogen). Subjective tolerability of the treatment and reported adverse effects will also be included as secondary outcomes. Another secondary outcome will consist of subjective scores from self-reported questionnaires,i.e. Diabetes-39, SF-36.
FIELD: medicine, cosmetology, veterinary science, pharmacy. SUBSTANCE: invention relates to the prepared semifinished product for preparing drug base containing placental material, drug base made of this semifinished product containing milled semifinished product prepared of placental material and special addition mixed with the base. Placental material forms mass exhibiting the novel structural properties that is treated with additions that retain its parent state and/or promoting the penetration of its biologically active substances through skin into human body and animal. Invention ensures to develop wasteless production of drugs, obtain semifinished product and the bases that retain biologically active substances in native state for a long time. EFFECT: semifinished product indicated above, wasteless production. 20 cl, 3 tbl, 11 ex
In accordance with the present invention, a novel composition has been discovered by extraction and purification from the spikes of Prunella vulgaris. Invention compositions are effective agents for treatment of the cytopathogenic effects of an enveloped virus in mammals. In accordance with another embodiment of the present invention, there are provided methods for the treatment of the cytopathogenic effects of an enveloped virus and related indications in mammals, employing the above-described novel compositions as the active agent. In accordance with yet another embodiment of the present invention, it has been discovered that invention compositions are effective agents for the treatment of the cytopathogenic effects of an enveloped virus in mammals exposed to immunosuppressive regimens. In accordance with still another embodiment of the present invention, it has been discovered that invention compositions provide an effective agent for protecting mammals from reactivated viral infection during or following treatment with chemotherapeutic agents. In accordance with a still further embodiment of the present invention, there are provided methods for preparing novel extracts of Prunella vulgaris having antiviral action and the formulations containing said extracts. In accordance with a still further embodiment of the present invention, there are provided methods for purification and characterization of the active fraction from Prunella vulgaris useful for treating the cytopathogenic effects of an enveloped virus in a mammal. In accordance with a still further embodiment of the present invention, it has been discovered that invention compositions are effective agents for the prophylaxis and therapy in mammals of diseases caused by enveloped viruses.
Sterile blunt-tip needles will be placed (without skin penetration) 20 mm away from the acupoints. The needle will be first inserted through a sterile plastic tube mounted on a foam block, and then pressed on the skin. The foam block compresses to give the impression that the needle is penetrating the skin, thus providing a SA effect. 'Pseudostimulation' will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
The present invention relates to a compound preparation for treating cold, particularly to an oral cavity disintegration tablet of pseudoephedrine hydrochloride and cholrphenamine maleate and a preparation method thereof. Most of the existing medicine for treating patients with cold on markets is taken with water. The oral cavity disintegration tablet of the present invention is formed by preparing main medicine and several kinds of supplementary material by a common press technique. The present invention has the advantages that the oral cavity disintegration tablet does not need to be taken by water, and the administration is convenient; the oral cavity disintegration tablet can be quickly disintegrated as long as the oral cavity disintegration tablet meets saliva in oral cavities, so the present invention brings convenience to patients who have the difficulty of swallow, the inconvenience of taking water and busy work. The present invention is particularly suitable for children and old people, and has broad market prospects. The present invention is a novel solid preparation which newly appears on the medicine market abroad. The product of the present invention is mainly used for treating and alleviating symptoms which are caused by common cold or influenza, such as fever, headache, painful limbs, sneezing, running noises, nasal occlusion, cough, pharyngalgia, etc.
NEW MATERIAL:A compound of the formula showing the following physicochemical properties. Molecular weight: 464; Molecular formula: C25H20O9; Mass spectrometric analysis: negative FAB-MSm/z 463 [M-H]-; Specific rotatory power: [alpha]D =+348 deg. (C=0.5, methanol); solubility: soluble in pyridine and methanol and sparingly soluble in water and n-hexane; Color reaction: dark blue coloring by FeCl3 reagent, Color: yellow acidic substance, etc. USE:An anti-cancer agent. PREPARATION:A semi-dried rhizome of a plant belonging to Davallia genus, especially Davallia meriesii Moor is subjected to extraction using an organic solvent such as ethanol or acetone or a mixture solution of an organic solvent and water. From the resultant extract, the objective new substance is isolated using a purification method consisting of a combination of filtration, condensation, extraction, washing, drying, recrystallization and various chromatography.
PROBLEM TO BE SOLVED: To provide a CKAP4-molecular-targeted antitumor agent.SOLUTION: The present invention provides an antitumor agent that inhibits the proliferation of tumor cells by suppressing the expression or function of Cytoskeleton-associated protein 4(CKAP4, 63-KDa Cytoskeleton-Linking Membrane Protein(CLIMP-63), P63, ERGIC-63)) as target molecules. The antitumor agent contains a material that inhibits bonding between CKAP4 and Dkk1 as an active ingredient. The antitumor agent is used for treating, preventing or inhibiting the progress of cancer. The cancer comprises one expressing CKAP4. The cancer further comprises one expressing Dkk1. The cancer comprises lung cancer or pancreatic cancer.SELECTED DRAWING: None
In the test group, GPCS (Silk, 4-0, 18 mm, 3/8 sharp needle) will be placed before the incision in the palatal region. GPCS will be taken one week after surgery.
Although many schizophrenia patients currently take oral antipsychotic medications, it is estimated that up to 75% of them have difficulty adhering to the daily oral regimen. Long-acting injectable formulations may eliminate the need for daily medication and enhance patient compliance with the treatment regimen. This safety study is an extension of a randomized, double-blind, multicenter, parallel group study that investigates effectiveness and safety of risperidone injected intramuscularly in patients with schizophrenia or schizoaffective disorder. The present open-label study evaluates 3 different doses of a formulation of risperidone injected into the muscle at 2 week intervals for at least 1 year in patients with these conditions. Assessments of effectiveness include the Clinical Global Impression (CGI) overall severity of illness scale. Quality of life will be assessed by the SF-36 Health Survey. Safety evaluations include incidence of adverse events, physical examinations, and evaluations of the injection site, clinical laboratory tests, electrocardiograms (ECGs), and Extrapyramidal Symptom Rating Scale (ESRS), a scale assessing muscle tone, gain, and abnormal movements. Injections every 2 weeks for at least 1 year, beginning at 25milligrams\[mg\] and increasing to 50mg or 75mg (maximum dose). Dosages may be increased or decreased at investigator's discretion. During the first 3 weeks, risperidone tablets (2mg) once daily to supplement injectable risperidone.
The patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and walking for 100 meters (i.e., the same treatment that will be administered to the Conventional Chest Physiotherapy group). Additionally, this group will receive positive airway pressure breathing with 15 mmHg by a device via a rubber facial mask for 30 minutes in a sitting position.
BACKGROUND AND OBJECTIVE: Regional analgesia is effective for post-thoracotomy pain. The primary objective of the study is to compare the intraoperative requirement of isoflurane and fentanyl between general anaesthesia (GA) with epidural analgesia and GA with paravertebral analgesia.
METHODS AND MATERIAL: A prospective observational comparative study was conducted on 56 patients undergoing open thoracotomy procedures. The patients were divided into two groups of 28 by assigning the study participants alternatively to each group: Group GAE - received thoracic epidural catheterization with GA, and Group GAP - received ultrasound guided thoracic paravertebral catheterization on the operative side with GA. Intraoperative requirement of isoflurane, fentanyl, postoperative analgesia, stress response, need of rescue analgesics and adverse effects were observed and analysed.
RESULTS: 25 patients in each group were included in the data analysis. The intraoperative requirement of isoflurane (32.28 ± 1.88 vs 48.31 ± 4.34 ml; p < 0.0001) and fentanyl (128.87 ± 25.12 vs 157 ± 30.92 μg; p = 0.0009) were significantly less in the GAE group than in the GAP group. VAS scores and need of rescue analgesics and blood glucose levels were not statistically significant during the postoperative period (p > 0.05). The incidence of adverse effects was comparable except for hypotension and urinary retention which were significantly higher in the GAE group.
CONCLUSION: GA with epidural analgesia resulted in significant reduction in the intraoperative consumption of isoflurane and fentanyl in comparison to GA with paravertebral analgesia. However, both the techniques were equally effective in the postoperative period.
The invention discloses a prescription of a traditional Chinese medicine for treating children bronchial asthma. Unit dosage of the traditional Chinese medicine comprises 6g of honeycomb, 6g of balloonflower root, 6g of fructus chebulae, 10g of lumbricus, 10g of radix stemonae, 10g of gingko fruits, 12g of perillaseeds and 3g of concretio silicea bambusae. In every day, one dosage of the traditional Chinese medicine is decocted through water and the soup is taken through 2-3 steps. A treatment course comprises 10 days. The prescription of the traditional Chinese medicine solves the problem that Children bronchial asthma is stubborn in routine drug treatment and the routine drug has large side effects, has a long use period, difficultly cures children bronchial asthma, usually causes recurrence and addiction, has a high recurrence rate after drug discontinuance and cannot thoroughly treat abdominal distension. The drug provided through the invention is suitable for treatment on children bronchial asthma.
Carpal tunnel syndrome (CTS) is one of the most common peripheral nerve entrapment disorders in the upper limb. CTS is common during pregnancy especially in the third trimester as well, a significant percentage of females postnatal may still have some complaints up to at least 3 years postnatal.

Purpose: To compare the effect of pulsed magnetic field (PEMF) versus ultrasound (US) in treating patients with CTS. Forty postnatal female patients with idiopathic CTS were assigned randomly into two equal groups. One group received PEMF with nerve and tendon gliding exercises for the wrist 3 times for week for 4 weeks. The other group received US plus the same exercises. Pain level, sensory and motor distal latencies of the median nerve (MSDL and MMDL), sensory and motor conduction velocities of the median nerve (MSCV and MMCV), functional status scale and hand grip strength were assessed pre and post treatment
The present invention relates to a cosmetic, pharmaceutical, and food compositions comprising veratric acid or a pharamaceutically acceptable salt thereof as an active ingredient for improving skin condition. The composition of the present invention has an excellent effect on alleviating wrinkle by increasing collagen synthesis and inhibiting an activity of collagenase, an enzyme which degrades collagen. Moreover, in the case where ultraviolet is irradiated, the present invention increases an amount of collagen, which is reduced due to the ultraviolet, and inhibits the activity of collagenase, which is enhanced by ultraviolet, to thereby exhibit an excellent effect on alleviating wrinkle. In addition, the present invention facilitates proliferation of hair follicle dermal papilla cells and secretion of IGF-1, which is a hair growth factor, and inhibits synthesis of TGF-beta 1, which is a hair growth inhibiting factor, to thereby exhibit effects on hair growth facilitation and hair loss prevention. Further, since the composition of the present invention is derived from a plant, which is a natural product, the present invention is nontoxic to human body and has no side effect on skin. Therefore, the present invention can be safely applied to a cosmetic, pharmaceutical and food compositions.
BACKGROUND: The prognostic value of left ventricular (LV) myocardial trabecular complexity on cardiovascular magnetic resonance (CMR) in dilated cardiomyopathy (DCM) remains unknown. This study aimed to evaluate the prognostic value of LV myocardial trabecular complexity using fractal analysis in patients with DCM.
METHODS: Consecutive patients with DCM who underwent CMR between March 2017 and November 2021 at two hospitals were prospectively enrolled. The primary endpoints were defined as the combination of all-cause death and heart failure hospitalization. The events of cardiac death alone were defined as the secondary endpoints.LV trabeculae complexity was quantified by measuring the fractal dimension (FD) of the endocardial border based on fractal geometry on CMR. Cox proportional hazards regression and Kaplan-Meier survival analysis were used to examine the association between variables and outcomes. The incremental prognostic value of FD was assessed in nested models.
RESULTS: A total of 403 patients with DCM (49.31 ± 14.68 years, 69% male) were recruited. After a median follow-up of 43 months (interquartile range, 28-55 months), 87 and 24 patients reached the primary and secondary endpoints, respectively. Age, heart rate, New York Heart Association functional class >II, N-terminal pro-B-type natriuretic peptide, LV ejection fraction, LV end-diastolic volume index, LV end-systolic volume index, LV mass index, presence of late gadolinium enhancement, global FD, LV mean apical FD, and LV maximal apical FD were univariably associated with the outcomes (all P < 0.05). After multivariate adjustment, LV maximal apical FD remained a significant independent predictor of outcome [hazard ratio = 1.179 (1.116, 1.246), P < 0.001]. The addition of LV maximal apical FD in the nested models added incremental prognostic value to other common clinical and imaging risk factors (all <0.001; C-statistic: 0.84-0.88, P < 0.001).
CONCLUSION: LV maximal apical FD was an independent predictor of the adverse clinical outcomes in patients with DCM and provided incremental prognostic value over conventional clinical and imaging risk factors.
STUDY OBJECTIVES: The aim of this study was to evaluate the physiological events associated with sleep bruxism (Sleep Bruxism [SB]; presence of mandibular movement activity) and the control window (4 minutes prior to SB event, where no mandibular movement activity was detected) in a polysomnography study in children with mild sleep apnea.
METHODS: Polysomnography data from children aged 4 to 9 years old diagnosed with mild sleep apnea were analyzed by 2 trained examiners. The mandibular movement activity (bruxism event; SB) was classified into phasic and tonic. The control window was selected 4 minutes prior to the SB event. All physiological events were recorded in both bruxism and control windows, including sleep phase (N1, N2, N3, and rapid eye movement), arousal, leg movements, tachycardia, bradycardia, oxygen desaturation, and number of obstructive and central sleep apnea events. The moment in which those phenomena occurred when associated with SB was also analyzed (before/after). Data were analyzed using 95% confidence intervals (α = 5%).
RESULTS: A total of 661 mandibular movements were analyzed and classified as tonic (n = 372) or phasic (n = 289). The mean apnea-hypopnea index was 1.99 (SD = 1.27) events/h. The frequency of leg movements, microarousal, and tachycardia was increased in SB events when compared with the control window (P < .05). There was an increase in bradycardia frequency in the control window when compared with SB (in both tonic and phasic events). The frequency of obstructive and central apnea during SB was lower when compared with the other physiological phenomena.
CONCLUSIONS: There is a difference in the physiological parameters evaluated in children with mild sleep apnea when comparing the 2 windows (SB and control). Sleep bruxism is associated with other physiological phenomena, such as leg movements, tachycardia, and microarousal. The use of a control window (where no mandibular activity was detected) was representative since it did not show activation of the sympathetic nervous system.
CITATION: Bonacina CF, Soster LMSFA, Bueno C, et al. Sleep bruxism and associated physiological events in children with obstructive sleep apnea: a polysomnographic study. J Clin Sleep Med. 2024;20(4):565-573.
PURPOSE: To obtain a prolactin secretion inhibitor that contains D-6-n-propyl-8β- hydroxymercaptomethylergoline as an effective ingredient together with inactive carriers, and excels in therapy of postpartum hyperlactation, galactorrhea, etc. CONSTITUTION: This prolactin secretion inhibitor contains a new compound, D-6-n-propyl-8β-hydroxymercaptomethylergoline, or its pharmacologically permissible acid addition salt as an effective ingredient together with inactive carriers. This prolactin secretion inhibitor is administered preferably by oral dosage in a dose of 0.01-0.5mg per kg of body weight in the form of a fitting-type gelatin capsule in which the effective ingredient is sealed as a mixture with a standard pharmacological excipient. The above-mentioned effective ingredient compound is synthesized, for example, by a reaction of a compound of formula I (Q is an eliminating group; X is H, Cl or Br; R<2> is H, ethyl, etc.) with a compound of formula II (Y is O, S, etc.).
INTRODUCTION: The fibrosis-4 (FIB-4) index and the fibrosis-5 (FIB-5) index are noninvasive markers of liver fibrosis in patients with nonalcoholic fatty liver disease. Although liver fibrosis a potential risk factor for stroke development, it is uncertain whether liver fibrosis influences stroke outcomes. We investigated the associations between these two indices and stroke patient outcomes and compared their predictive accuracy.
METHODS: We conducted a double-center, hospital-based, retrospective study. Consecutive acute ischemic stroke patients (n=2399) were analyzed. We calculated the FIB-4 index and the FIB-5 index and evaluated their relationships with poor stroke outcome, which was defined as a modified Rankin Scale score of 3-6 at three months after stroke. We evaluated the ability of each index to predict stroke outcome according to cutoff values calculated from receiver operating characteristic (ROC) curves.
RESULTS: Of 2399 recruited patients, 1549 patients (mean age, 73 years) were analyzed. The FIB-4 index and FIB-5 index had similar areas under their ROC curves for predicting stroke outcome (FIB-4 index, 0.675 and FIB-5 index, 0.683, P=0.334). The cutoff points of the FIB-4 index and FIB-5 index according to the ROC analysis were associated with poor stroke outcome in the multivariable analyses (odds ratio [OR] 2.23, 95 % confidence interval [CI] 1.72-2.89, OR 1.93, 95 % CI 1.47-2.54, respectively).
CONCLUSIONS: Liver fibrosis scores may be useful for predicting outcomes in patients with acute stroke. The FIB-4 and FIB-5 indices should be considered comprehensive tools for assessing the outcome risk after ischemic stroke.